Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

OptimizeRx (OPRX) Other Operating Expenses: 2009-2024

Historic Other Operating Expenses for OptimizeRx (OPRX) over the last 16 years, with FY2024 value amounting to $23.2 million.

  • OptimizeRx's Other Operating Expenses fell 8741.85% to $1.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $21.6 million, marking a year-over-year increase of 7932.21%. This contributed to the annual value of $23.2 million for FY2024, which is 118188.61% up from last year.
  • Per OptimizeRx's latest filing, its Other Operating Expenses stood at $23.2 million for FY2024, which was up 118188.61% from -$2.1 million recorded in FY2023.
  • In the past 5 years, OptimizeRx's Other Operating Expenses ranged from a high of $23.2 million in FY2024 and a low of -$20.2 million during FY2021
  • Moreover, its 5-year median value for Other Operating Expenses was -$2.1 million (2023), whereas its average is -$2.0 million.
  • Per our database at Business Quant, OptimizeRx's Other Operating Expenses tumbled by 49246.24% in 2021 and then soared by 118188.61% in 2024.
  • Over the past 5 years, OptimizeRx's Other Operating Expenses (Annual) stood at $5.2 million in 2020, then plummeted by 492.46% to -$20.2 million in 2021, then grew by 20.11% to -$16.2 million in 2022, then surged by 86.74% to -$2.1 million in 2023, then skyrocketed by 1181.89% to $23.2 million in 2024.
  • Its last three reported values are $23.2 million in FY2024, -$2.1 million for FY2023, and -$16.2 million during FY2022.